Periotherapia Co.,Ltd. is pleased to announce that our project, selected in FY2023 under the Japan Agency for Medical Research and Development (AMED) “Drug Discovery Venture Ecosystem Enhancement Program (Open Call for Drug Discovery Ventures)” (3rd round), has successfully passed the midterm stage-gate review and has been formally approved to transition to Stage 2.

Under this program, we are advancing our project, “Development of a Novel Therapeutic Approach for Treatment-Resistant Metastatic/Recurrent HER2-Negative Breast Cancer.” With AMED’s continued support, we will further accelerate our efforts to execute a domestic Phase 1/2a clinical trial and to drive the initiation and conduct of clinical trials in North America. We remain fully committed to delivering innovative treatment options to patients as quickly as possible.

令和7年度「創薬ベンチャーエコシステム強化事業（創薬ベンチャー公募）」中間評価（ステージゲート評価）（4）の結果について

We would also like to express our sincere gratitude to Osaka University Venture Capital Co., Ltd. (OUVC) , Mitsubishi UFJ Capital Co., Ltd. (MUCAP), Eisai Innovation, Inc. as well as to all of our shareholders and business partners, for their ongoing support and collaboration.